CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated: Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reviewed its recent development progress in hepatitis C (HCV) and cystic fibrosis (CF), reported consolidated financial results for the year ended December 31, 2008 and provided financial guidance for 2009.
